The agency is holding a public hearing next month on CBD products. CBD is short for cannabidoil, one of the ingredients in cannabis.
It is marketed for everything from helping to relieve pain to reducing stress and anxiety, but the ingredient is not sanctioned by the FDA.
Federal officials want to discuss developing a regulatory framework for the use of CBD in products.
The public hearing is scheduled for May 31st.